Multi-spanning membrane proteins are targets of half of all small molecule drugs but only 3 therapeutic monoclonal antibodies (MAbs).
THE INDUSTRY LEADER IN MEMBRANE PROTEIN SOLUTIONS
Integral Molecular Introduces Influenza RVPs
Integral Molecular Inaugurates its New Research Center on April 20, 2023
Integral Molecular Publishes Mechanism of Claudin 6 Therapeutic Antibody
Systematic analysis of human antibody response to ebolavirus glycoprotein shows high prevalence of neutralizing public clonotypes
Cell Reports, 2023
Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity
Nature Communications, 2023
Antibody specificity against highly conserved membrane protein Claudin 6 driven by single atomic contact point
Why Are There So Few Therapeutic Antibodies Against Complex Membrane Proteins?
MAbs offer therapeutic advantages of exquisite specificity, safety, and bioavailability and are twice as likely as small molecules to succeed in clinical trials. However, due to the complex structure and high homology of membrane protein targets, MAbs against them are difficult to generate, isolate and characterize.
Integral Molecular Enables Membrane Protein Antibody Discovery
With a 95% success rate, Integral Molecular is the leader in isolating MAbs against complex membrane proteins, including GPCRs, ion channels, transporters and viral proteins.
Integral Molecular’s technologies have contributed to scientific discoveries featured in 430+ peer-reviewed publications.
Your success is crucial to us. We work hard to understand your needs, and strive to exceed your expectations.
Membrane Protein Solutions
430+ Publications Including Cell, Science & Nature
Trusted by 400+ Companies
Ready To Get Started?
We have worked with more than 100 top biotech and pharmaceutical companies to help them succeed. Let’s talk about how we can help you.